199 related articles for article (PubMed ID: 22068148)
1. SP600125 inhibits Orthopoxviruses replication in a JNK1/2 -independent manner: Implication as a potential antipoxviral.
Pereira AC; Soares-Martins JA; Leite FG; Da Cruz AF; Torres AA; Souto-Padrón T; Kroon EG; Ferreira PC; Bonjardim CA
Antiviral Res; 2012 Jan; 93(1):69-77. PubMed ID: 22068148
[TBL] [Abstract][Full Text] [Related]
2. A vaccinia virus-driven interplay between the MKK4/7-JNK1/2 pathway and cytoskeleton reorganization.
Pereira AC; Leite FG; Brasil BS; Soares-Martins JA; Torres AA; Pimenta PF; Souto-Padrón T; Traktman P; Ferreira PC; Kroon EG; Bonjardim CA
J Virol; 2012 Jan; 86(1):172-84. PubMed ID: 22031940
[TBL] [Abstract][Full Text] [Related]
3. JNK1/2 inhibitor reduces dengue virus-induced liver injury.
Sreekanth GP; Chuncharunee A; Cheunsuchon B; Noisakran S; Yenchitsomanus PT; Limjindaporn T
Antiviral Res; 2017 May; 141():7-18. PubMed ID: 28188818
[TBL] [Abstract][Full Text] [Related]
4. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses.
Smee DF; Sidwell RW; Kefauver D; Bray M; Huggins JW
Antimicrob Agents Chemother; 2002 May; 46(5):1329-35. PubMed ID: 11959564
[TBL] [Abstract][Full Text] [Related]
5. The c-Jun N-terminal kinase inhibitor SP600125 inhibits human cytomegalovirus replication.
Zhang H; Niu X; Qian Z; Qian J; Xuan B
J Med Virol; 2015 Dec; 87(12):2135-44. PubMed ID: 26058558
[TBL] [Abstract][Full Text] [Related]
6. Identification of CP77 as the Third Orthopoxvirus SAMD9 and SAMD9L Inhibitor with Unique Specificity for a Rodent SAMD9L.
Zhang F; Meng X; Townsend MB; Satheshkumar PS; Xiang Y
J Virol; 2019 Jun; 93(12):. PubMed ID: 30918078
[TBL] [Abstract][Full Text] [Related]
7. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge.
Yang G; Pevear DC; Davies MH; Collett MS; Bailey T; Rippen S; Barone L; Burns C; Rhodes G; Tohan S; Huggins JW; Baker RO; Buller RL; Touchette E; Waller K; Schriewer J; Neyts J; DeClercq E; Jones K; Hruby D; Jordan R
J Virol; 2005 Oct; 79(20):13139-49. PubMed ID: 16189015
[TBL] [Abstract][Full Text] [Related]
8. Study of vaccinia and cowpox viruses' replication in Rac1-N17 dominant-negative cells.
Salgado AP; Soares-Martins JA; Andrade LG; Albarnaz JD; Ferreira PC; Kroon EG; Bonjardim CA
Mem Inst Oswaldo Cruz; 2013 Aug; 108(5):554-62. PubMed ID: 23903969
[TBL] [Abstract][Full Text] [Related]
9. Specific targeting of the F13L protein by ST-246 affects orthopoxvirus production differently.
Duraffour S; Vigne S; Vermeire K; Garcel A; Vanstreels E; Daelemans D; Yang G; Jordan R; Hruby DE; Crance JM; Garin D; Andrei G; Snoeck R
Antivir Ther; 2008; 13(8):977-90. PubMed ID: 19195323
[TBL] [Abstract][Full Text] [Related]
10. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
Quenelle DC; Prichard MN; Keith KA; Hruby DE; Jordan R; Painter GR; Robertson A; Kern ER
Antimicrob Agents Chemother; 2007 Nov; 51(11):4118-24. PubMed ID: 17724153
[TBL] [Abstract][Full Text] [Related]
11. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections.
Baker RO; Bray M; Huggins JW
Antiviral Res; 2003 Jan; 57(1-2):13-23. PubMed ID: 12615299
[TBL] [Abstract][Full Text] [Related]
12. Increased susceptibility of Cantagalo virus to the antiviral effect of ST-246®.
Santos-Fernandes É; Beltrame CO; Byrd CM; Cardwell KB; Schnellrath LC; Medaglia ML; Hruby DE; Jordan R; Damaso CR
Antiviral Res; 2013 Mar; 97(3):301-11. PubMed ID: 23257396
[TBL] [Abstract][Full Text] [Related]
13. Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections.
Kern ER; Prichard MN; Quenelle DC; Keith KA; Tiwari KN; Maddry JA; Secrist JA
Antimicrob Agents Chemother; 2009 Feb; 53(2):572-9. PubMed ID: 19029322
[TBL] [Abstract][Full Text] [Related]
14. Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro.
Smee DF; Bray M; Huggins JW
Antivir Chem Chemother; 2001 Nov; 12(6):327-35. PubMed ID: 12018677
[TBL] [Abstract][Full Text] [Related]
15. Small molecule inhibitors of the c-Jun N-terminal kinase (JNK) possess antiviral activity against highly pathogenic avian and human pandemic influenza A viruses.
Nacken W; Ehrhardt C; Ludwig S
Biol Chem; 2012 May; 393(6):525-34. PubMed ID: 22628315
[TBL] [Abstract][Full Text] [Related]
16. RNase L induces autophagy via c-Jun N-terminal kinase and double-stranded RNA-dependent protein kinase signaling pathways.
Siddiqui MA; Malathi K
J Biol Chem; 2012 Dec; 287(52):43651-64. PubMed ID: 23109342
[TBL] [Abstract][Full Text] [Related]
17. Effect of Jun N-terminal kinase 1 and 2 on the replication of Penicillium marneffei in human macrophages.
Chen R; Xi L; Huang X; Ma T; Ren H; Ji G
Microb Pathog; 2015 May; 82():1-6. PubMed ID: 25792289
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of c-Jun-N-terminal-kinase sensitizes tumor cells to CD95-induced apoptosis and induces G2/M cell cycle arrest.
Kuntzen C; Sonuc N; De Toni EN; Opelz C; Mucha SR; Gerbes AL; Eichhorst ST
Cancer Res; 2005 Aug; 65(15):6780-8. PubMed ID: 16061660
[TBL] [Abstract][Full Text] [Related]
19. Stress-activated protein kinases are involved in coxsackievirus B3 viral progeny release.
Si X; Luo H; Morgan A; Zhang J; Wong J; Yuan J; Esfandiarei M; Gao G; Cheung C; McManus BM
J Virol; 2005 Nov; 79(22):13875-81. PubMed ID: 16254323
[TBL] [Abstract][Full Text] [Related]
20. c-Jun NH2-terminal kinase inhibitor anthra(1,9-cd)pyrazol-6(2H)-one reduces inducible nitric-oxide synthase expression by destabilizing mRNA in activated macrophages.
Lahti A; Jalonen U; Kankaanranta H; Moilanen E
Mol Pharmacol; 2003 Aug; 64(2):308-15. PubMed ID: 12869635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
